When compared to a placebo, SGLT2 inhibitors reduced the risk of primary cardiovascular outcomes by 26% (HR 0.74, [95% CI 0.69–0.80], I2 = 0.00%) in patients with stage 3/4 CKD (Fig 2). This evidence concerns the gene SLC5A2 and chronic kidney disease.